Skip to main content

Advertisement

Fig. 1 | Molecular Cancer

Fig. 1

From: METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma

Fig. 1

METTL3 is highly expressed in metastatic CRC and associated with poor prognosis. a Heat map profiling the expression of m6A WERs in the TCGA database of COAD. b Real-time PCR analysis of m6A WER expression in 48 paired CRC tumor tissues (T) and adjacent normal tissues (N). c Real-time PCR analysis of METTL3 expression in CRC tissues from patients with recurrence (R, n = 48) and without recurrence (T, n = 48), 28 paired liver metastatic tissues (LM) versus primary tumor tissues (T), and adjacent normal tissues (N). d-e Real-time PCR analysis and Immunoblotting assay of METTL3 expression in normal colonic epithelial cell lines and CRC cell lines. f Immunoblotting assay of METTL3 expression in eight paired CRC primary tumor samples (T) and adjacent normal tissues (N). g Representative images showing METTL3 expression in CRC adjacent normal tissues (ANT) (upper) versus high METTL3 expression in CRC tumor tissues (T) (lower) (scale bar: 100 μm). h METTL3 IHC staining scores in CRC tumor tissues versus ANT (n = 432), paired lymph node metastatic tissues (LNM, n = 52) or paired liver metastatic tissues (LM, n = 43). i Correlation between METTL3 expression with CRC patient response to FOLFOX or XELOX chemotherapy. The data were analyzed by Pearson’s Chi-square test. j Kaplan-Meier analysis of OS time (upper) and DFS time (lower) based on METTL3 expression. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. The data in b, c, d, and i, are presented as the mean ± SDs (n = 3). *P < 0.05, **P < 0.01 (Student’s t-test). β-Actin was used as the loading control

Back to article page